scout

Authors

David A. Asch, MD, MBA
Latest Article

Commentary (Asch): Some Elements of Prognosis in Terminal Cancer

You’ve got to accentuate the positive,Eliminate the negative,Latch onto the affirmative,Don’t mess with Mister In-between.-Johnny Mercer, 1944

David A. August, MD
Latest Article

Expert Consultations in Breast Cancer: Critical Pathways and Clinical Decision Making

This book is the 17th volume in the Basic and Clinical Oncology series edited by Bruce D. Cheson, MD. Like other volumes in this series, Expert Consultations in Breast Cancer follows a unique format and seeks to integrate advances in the basic understanding of breast cancer with promising new therapies and changing health- care economics. The integration of these different perspectives provides both a conceptual and pragmatic framework for clinical decision-making.

David A. Bush, MD
Latest Article

Proton Radiation Therapy for Lung Cancer: Is There Enough Evidence?

Proton radiation for cancer offers the ability to conform the high-dose region of radiation therapy to the tumor while reducing the dose of radiation to adjacent normal tissues. In lung cancer, this equates to greater sparing of uninvolved lung, heart, esophagus, and spinal cord. Sparing these normal tissues permits the delivery of higher-radiation doses to the tumor. Studies that compare the distribution of radiation doses for lung cancer show that proton radiation is superior, even when factors such as respiratory motion are considered. Clinical experience confirms the feasibility of proton radiation for early-stage non-small-cell lung cancers, and clinical trials are being conducted in locally advanced tumors: To date, evidence indicates that proton radiation should be further explored.

David A. Kooby, MD
Latest Article

Neuroendocrine Tumors: a Heterogeneous Set of Neoplasms

The review of surgical management of neuroendocrine tumors (NETs) of the gastrointestinal tract, authored by Huang, Poultsides, and Norton, is both comprehensive and accessible for readers of all backgrounds.

David A. Reardon, MD
Latest Article

Addressing Hepatotoxicity in Clinical Practice for IDH-Mutant Gliomas

Panelists discuss how to manage borderline transaminase elevations in a patient benefiting from voracidinib therapy, balancing the risk of mild liver toxicity against continued disease control while investigating potential contributing factors.

David A. Rothenberger, MD
Latest Article

Complete Guide to Colorectal Cancer

Nearly 150,000 people will be diagnosed with colorectal cancer in the United States in 2006. The impact of this diagnosis will be felt by countless family members, coworkers, and friends. Although screening tests for colorectal cancer have been available and encouraged by medical associations such as the American Cancer Society (ACS) and others, public awareness and compliance has been dismal.

David Aboulafia, MD
Latest Article

Epidemiology and Pathogenesis of AIDS-Related Lymphomas

Among patients with congenital and acquired immunodeficiencies, non-Hodgkin’s lymphomas (NHLs) are the most common tumors of the immune system. In the setting of human immunodeficiency virus (HIV) infection, as

David Albertson, MD
Latest Article

Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer

Early clinical studies combining irinotecan (CPT-11, Camptosar) and gemcitabine (Gemzar) have yielded encouraging results. Gemcitabine administered via a twice-weekly schedule results in an enhanced radiation-sensitizing effect.

David B. Mansur, MD
Latest Article

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma

By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.

David B. Page, MD
Latest Article

CTLA-4 Antibodies: New Directions, New Combinations

This review will summarize the preclinical and clinical development of CTLA-4–blocking antibodies, discuss recent insights into the biology of CTLA-4 blockade, review the use of these antibodies in combination with established and novel therapeutic modalities, and comment on ongoing questions regarding their administration.

David B. Sanford, MD
Latest Article

Hodgkin's Disease

Although there have been many advances in the treatment of Hodgkin's disease, diagnosis of the disease still rests on the identification of the Reed-Sternberg cell. This distinctive, though nonspecific, cell was first described by Sternberg in 1898 and further elucidated by Reed in 1902. In most biopsies, the Reed-Sternberg cell accounts for only 1% of the cells present, with the remainder consisting of lymphocytes, granulocytes, histiocytes, plasma cells, and fibroblasts

David Berd, MD
Latest Article

Commentary (Berd)-Melanoma Vaccines: What We Know So Far

There have been an astoundingnumber of published reviewson human cancer vaccines, andI take responsibility for my share. Apparentlythe interest of the medicalcommunity in cancer vaccines remainsintense, despite the modest progressthat has been made in our field and thepaucity of convincing, positive clinicalresults. Somehow the idea of treatinga cancer by inducing an antitumorimmune response or strengthening theexisting one is strongly appealing bothto physicians and to patients. Whetherthis enthusiasm is justified by the scienceis a question that should troublethe sleep of all of us who call ourselvestumor immunologists.

David Borquez, MD
Latest Article

Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer

This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral

David Bostwick, MD
Latest Article

Microvessel Density in Needle Biopsies May Help Predict Stage

A total of 186 randomly selected needle biopsies were evaluated and radical prostatectomy samples were matched with preoperative PSA concentration and patient demographics. Gleason score and optimized microvessel density were determined from the needle biopsy samples; pathologic stage was verified by independent review of the prostatectomy samples. An automated digital image analysis system measured microvessel morphology and calculated the optimized microvessel density in biopsies. Using this system in combination with the Gleason score and serum PSA significantly increases the ability to predict extraprostatic extension of cancer preoperatively. [Oncol News Int 6(Suppl 3):13-14, 1997]

David Bregman, MD
Latest Article

Novel Combinations With Oxaliplatin

Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA replication/transcription, thus resulting in cell death in proliferating cells, as well as apoptosis.

David C. Beyer, MD
Latest Article

Proton Therapy for Prostate Cancer: Show Me the CER!

Hoppe et al present an excellent review of the physics relevant to an understanding of proton therapy-and of the available literature assessing the use of proton beams in the management of prostate cancer.

David C. Hodgson, MD
Latest Article

ACR Appropriateness Criteria® Localized Nodal Indolent Lymphoma

The present guidelines review epidemiology, pathology, presentation, workup, staging, prognostic factors, and treatment options for patients with localized nodal indolent lymphoma, with an emphasis on radiation guidelines, including radiation dose, field design, and radiation techniques.

David C. Linch, MD
Latest Article

Current Issues in the Treatment of Resistant Bloodstream Infections

Bloodstream infections cause significant morbidity and mortality for patients with hematologic malignancy. Antimicrobial drugs are the most reliable currently available treatment for infection, but several issues must be

David C. Rice, MB
Latest Article

Further Considerations in the Treatment of Locally Advanced Lung Cancer

Probably no other topic in thoracic oncology has resulted in more controversy than that of the management of locally advanced non–small-cell lung cancer (NSCLC). Although recent large randomized studies have yielded more reliable and objective data on which to base treatment decisions than were available a decade ago, management of these patients is still influenced by specialty bias and philosophical beliefs.

David C. Seldin, MD, PhD
Latest Article

AL Amyloidosis: Who, What, When, Why, and Where

In the current issue of ONCOLOGY, Gertz and Dispenzieri provide a scholarly review of the early recognition, diagnosis, and treatment of immunoglobulin light-chain (AL) amyloidosis.

David C. Smith, MD
Latest Article

Commentary (Smith/Sandler)-Testicular Cancer: Maintaining the High Cure Rate

As Dr. Raghavan has emphasizedin his excellent overviewof the current therapyfor testis cancer, it is critical that thesuccess of therapy for this diseasenot be compromised by a desire toavoid the complications of therapy.We would wholeheartedly agree withhis assertion that modifications intherapy must be introduced with athoughtful and structured approachto minimize the risk to efficacy.

David C. Tabor, MD
Latest Article

Physicians Must Unite Against New Bureaucratic ‘Hassles’ to Practicing Medicine

I read with interest the article based on a presentation by Dr. David Hussey concerning physician competency reviews (December 2000). Dr. Hussey, who is president of the American Society for Therapeutic Radiology and Oncology

David Cachia, MD, MRCP
Latest Article

Glioma-Associated Fatigue and Cognitive Dysfunction

In this interview we discuss fatigue, cognitive dysfunction, and psychiatric problems in patients with glioma and review which patients are more likely to encounter these issues.

David Cella, PhD
Latest Article

Age Matters... Or Does It?

Anemia raises special concerns in older cancer patients. This review addresses the prevalence, causes, and mechanisms of anemia in older individuals, the complications of anemia in this population (including its impact on cancer treatment), and the appropriate management of anemia in the elderly.

David Coeffic, MD
Latest Article

European Experience With Irinotecan Plus Fluorouracil/Folinic Acid or Mitomycin

Tremendous progress has been made in the medical treatment of advanced colorectal cancer during the past 2 to 3 years, due to the availability of several new drugs. Of these new agents, irinotecan (CPT-11 [Camptosar]) seems

David Crockett, MD
Latest Article

Synchronous Bilateral Breast Cancer With Discordant Histology

A 48-year-old Caucasian woman presented with a palpable right breast mass. Physical examination confirmed a lump on the upper outer quadrant of her right breast. On PET/CT scan there was an incidental finding of increased metabolic activity in the left lateral breast.

David Cundiff, MD
Latest Article

Book Review: Euthanasia is Not the Answer-A Hospice Physician's View

Recent broad interest in euthanasia and assisted suicide by society at large has prompted this review of euthanasia. This fine,

David Cunningham, MD, FRCP
Latest Article

Therapeutic Options in Gastric Cancer: Neoadjuvant Chemotherapy vs Postoperative Chemoradiotherapy

The majority of patients who undergo resection for gastric cancer experience relapse and ultimately die of their disease. Therefore, considerable attention has been paid to neoadjuvant and adjuvant strategies to improve surgical outcomes. Two different approaches have been tested in major clinical trials conducted in the past several years: Postoperative chemoradiotherapy was assessed in a US Southwest Oncology Group/Intergroup study (SWOG 9008/INT 0116), and perioperative chemotherapy was studied in a UK Medical Research Council (MRC) randomized trial (the MRC Adjuvant Gastric Infusional Chemotherapy [MAGIC] trial). These trials demonstrated statistically significant survival benefits in patients with resectable gastric cancer. This review will consider these trials and their implications for clinical practice.

David Dorr, MD, MS
Latest Article

Reporting Only ‘Unanticipated’ AEs of Trial Drugs Would Reduce IRB Workload, But Would Patient Safety Suffer?

Enrollment in clinical trials is crucialto continued scientific discovery andimproved patient care.

David E. Cohn, MD
Latest Article

Gynecologic Malignancies in Older Women

The demographics of the US population continue to change dramatically, as the absolute number and proportion of older people relative to the remainder of the population increases. Last year, the number of persons older than 65 years was estimated to be 35 million, representing almost 13% of the overall population; by 2030, the older population is expected to double. Along with the general aging of the population, the percentage of persons older than 85 years is also growing rapidly, as is the ethnic and racial diversity within the older population.